Share：
Share this content in WeChat
X
[Chinese][PDF]92881
• Review •
MR study on neuromyelitis optica and multiple sclerosis: A review on different MRI technique
MA Xiao-xiao  LOU Xin 

DOI:10.12015/issn.1674-8034.2016.12.011.


[Abstract] Neuromyelitis optica (NMO) has different pathophysiology, approaches to treatment and prognosis from multiple sclerosis (MS). Not timely and improper treatment may lead to deterioration or even relapse of the disease, seriously affecting the life quality of patients. Correctly differentiation of NMO from MS plays a pivotal role in prognosis and treatment strategy. Morphology and distribution of lesions can be observed on conventional MRI. Additionally, advanced MRI provides an insight into the underlying pathology. This literature review summarizes the study on NMO and MS using conventional and advanced MRI.
[Keywords] Neuromyelitis optica；Multiple sclerosis；Magnetic resonance imaging

MA Xiao-xiao Department of Radiology, Chinese PLA General Hospital, Beijing 100853, China

LOU Xin* Department of Radiology, Chinese PLA General Hospital, Beijing 100853, China

*Correspondence to: Lou X, E-mail: louxin301@gmail.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of National Natural Science Foundation of China No. 81671126
Received  2016-10-10
Accepted  2016-11-25
DOI: 10.12015/issn.1674-8034.2016.12.011
DOI:10.12015/issn.1674-8034.2016.12.011.

[1]
Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler, 2014, 20(6): 695-704.
[2]
Liu Y, Duan Y, Huang J, et al. Multimodal quantitative MR imaging of the thalamus in multiple sclerosis and neuromyelitis optica. Radiology, 2015, 277(3): 784-792.
[3]
Jurynczyk M, Craner M, and Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry, 2015, 86(1): 20-25.
[4]
Sinnecker T, Dorr J, Pfueller CF, et al. Distinct lesion morphology at 7.0 T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology, 2012, 79(7): 708-714.
[5]
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, 2015, 85(2): 177-189.
[6]
Barnett Y, Sutton IJ, Ghadiri M, et al. Conventional and advanced imaging in neuromyelitis optica. AJNR Am J Neuroradiol, 2014, 35(8): 1458-1466.
[7]
Popescu BF, Pirko I, and Lucchinetti CF. Pathology of multiple sclerosis: where do we stand?. Continuum (Minneap Minn), 2013, 19(4): 901-921.
[8]
Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain, 2002, 125(Pt 7): 1450-1461.
[9]
Wegner C. Recent insights into the pathology of multiple sclerosis and neuromyelitis optica. Clin Neurol Neurosurg, 2013, 115(Suppl 1): S38-41.
[10]
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol, 2011, 69(2): 292-302.
[11]
Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol, 2006, 63(7): 964-968.
[12]
Cabrera-Gomez JA, Quevedo-Sotolongo L, Gonzalez-Quevedo A, et al. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler, 2007, 13(2): 186-192.
[13]
Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler, 2010, 16(10): 1229-1236.
[14]
Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology, 2015, 84(11): 1165-1173.
[15]
Kim W, Kim SH, Huh SY, et al. Brain abnormalities in neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2011, 302(1-2): 43-48.
[16]
Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology, 2011, 76(14): 1229-1237.
[17]
Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology, 2013, 80(14): 1330-1337.
[18]
Chen Z, Feng F, Yang Y, et al. MR imaging findings of the corpus callosum region in the differentiation between multiple sclerosis and neuromyelitis optica. Eur J Radiol, 2012, 81(11): 3491-3495.
[19]
Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler, 2009, 15(6): 695-700.
[20]
Cabrera-Gomez J, Saiz-Hinarejos A, Graus F, et al. Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Mult Scler, 2008, 14(2): 248-251.
[21]
Viegas S, Weir A, Esiri M, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry, 2009, 80(6): 679-682.
[22]
Qiu W, Raven S, Wu JS, et al. Hypothalamic lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry, 2011, 82(7): 819-822.
[23]
Kremer S, Renard F, Achard S, et al. Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol, 2015, 72(7): 815-822.
[24]
Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica, An MRI study. J Neurol, 2008, 255(2): 163-170.
[25]
Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol, 2012, 32(3): 216-220.
[26]
Storoni M, Davagnanam I, Radon M, et al. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol, 2013, 33(2): 123-127.
[27]
Roosendaal SD, Geurts JJ, Vrenken H, et al. Regional DTI differences in multiple sclerosis patients. Neuroimage, 2009, 44(4): 1397-1403.
[28]
Rueda Lopes FC, Doring T, Martins C, et al. The role of demyelination in neuromyelitis optica damage: diffusion-tensor MR imaging study. Radiology, 2012, 263(1): 235-242.
[29]
Yu C, Lin F, Li K, et al. Pathogenesis of normal-appearing white matter damage in neuromyelitis optica: diffusion-tensor MR imaging. Radiology, 2008, 246(1): 222-228.
[30]
Zhao DD, Zhou HY, Wu QZ, et al. Diffusion tensor imaging characterization of occult brain damage in relapsing neuromyelitis optica using 3.0 T magnetic resonance imaging techniques. Neuroimage, 2012, 59(4): 3173-3177.
[31]
Amann M, Papadopoulou A, Andelova M, et al. Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. J Neurol, 2015, 262(8): 1909-1917.
[32]
Rocca MA, Agosta F, Mezzapesa DM, et al. Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology, 2004, 62(3): 476-478.
[33]
Pichiecchio A, Tavazzi E, Poloni G, et al. Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach. Mult Scler, 2012, 18(6): 817-824.
[34]
Duan Y, Liu Y, Liang P, et al. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study. Eur J Radiol, 2012, 81(2): 110-114.
[35]
Chanson JB, Lamy J, Rousseau F, et al. White matter volume is decreased in the brain of patients with neuromyelitis optica. Eur J Neurol, 2013, 20(2): 361-367.
[36]
Blanc F, Noblet V, Jung B, et al. White matter atrophy and cognitive dysfunctions in neuromyelitis optica. PLos One, 2012, 7(4): e33878.
[37]
Weier K, Eshaghi A, Magon S, et al. The role of cerebellar abnormalities in neuromyelitis optica: a comparison with multiple sclerosis and healthy controls. Mult Scler, 2015, 21(6): 757-766.
[38]
Rocca MA, Agosta F, Mezzapesa DM, et al. A functional MRI study of movement-associated cortical changes in patients with Devic's neuromyelitis optica. Neuroimage, 2004, 21(3): 1061-1068.
[39]
Ciccarelli O, Thomas DL, De Vita E, et al. Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. Ann Neurol, 2013, 74(2): 301-305.
[40]
de Seze J, Blanc F, Kremer S, et al. Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol Neurosurg Psychiatry, 2010, 81(4): 409-411.
[41]
Aboul-Enein F, Krssak M, Hoftberger R, et al. Diffuse white matter damage is absent in neuromyelitis optica. AJNR Am J Neuroradiol, 2010, 31(1): 76-79.
[42]
Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology, 2012, 78(5): 302-308.
[43]
Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med, 2011, 365(23): 2188-2197.
[44]
Popescu BF, Parisi JE, Cabrera-Gomez JA, et al. Absence of cortical demyelination in neuromyelitis optica. Neurology, 2010, 75(23): 2103-2109.
[45]
Saji E, Arakawa M, Yanagawa K, et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol, 2013, 73(1): 65-76.
[46]
Calabrese M, Oh MS, Favaretto A, et al. No MRI evidence of cortical lesions in neuromyelitis optica. Neurology, 2012, 79(16): 1671-1676.
[47]
Mainero C, Benner T, Radding A, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI, Neurology, 2009, 73(12): 941-948.
[48]
Kister I, Herbert J, Zhou Y, et al. Ultrahigh-Field MR (7.0 T) Imaging of Brain Lesions in Neuromyelitis Optica. Mult Scler Int, 2013, 2013(15): 398259.
[49]
Habib CA, Liu M, Bawany N, et al. Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls. AJNR Am J Neuroradiol, 2012, 33(2): 252-258.
[50]
Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage, 2012, 59(1): 331-339.
[51]
Langkammer C, Schweser F, Krebs N, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage, 2012, 62(3): 1593-1599.
[52]
Doring TM, Granado V, Rueda F, et al. Quantitative susceptibility mapping indicates a disturbed brain iron homeostasis in neuromyelitis optica: A pilot study. PLos One, 2016, 11(5): 155027.
[53]
Chen X, Zeng C, Luo T, et al. Iron deposition of the deep grey matter in patients with multiple sclerosis and neuromyelitis optica: a control quantitative study by 3D-enhanced susceptibility-weighted angiography (ESWAN). Eur J Radiol, 2012, 81(4): 633-639.
[54]
Tallantyre EC, Morgan PS, Dixon JE, et al. A comparison of 3 T and 7.0 T in the detection of small parenchymal veins within MS lesions. Invest Radiol, 2009, 44(9): 491-494.
[55]
Sinnecker T, Schumacher S, Mueller K, et al. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7.0 T. Neurol Neuroimmunol Neuroinflamm, 2016, 3(4): 259.
[56]
Chawla S, Kister I, Wuerfel J, et al. Iron and non-iron-related characteristics of multiple sclerosis and neuromyelitis optica Lesions at 7.0 T MRI. AJNR Am J Neuroradiol, 2016, 37(7): 1223-1230.

PREV Intraosseous malignant peripheral nerve sheath tumor of the fibula: A case report
NEXT Application of multimodality fMRI in preterm brain injury
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn